{"id":117683,"date":"2026-03-04T09:46:00","date_gmt":"2026-03-04T08:46:00","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=117683"},"modified":"2026-03-03T15:40:03","modified_gmt":"2026-03-03T14:40:03","slug":"rnatics-receives-new-funding","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/117683\/rnatics-receives-new-funding\/","title":{"rendered":"A milestone in the treatment of lung diseases? Rnatics receives 2.7 million euros."},"content":{"rendered":"<div class=\"entry-content\">\n<p>Rnatics has received \u20ac2.7 million from the German Federal Ministry for Research, Technology and Space (BMFTR). The spin-off from the Technical University of Munich will use the funding for the clinical development of the RNA drug RCS-21. <a href=\"\/en\/startups\/rnatics-gmbh\/\">Pursue<\/a> This will advance the preparation of clinical trials.<\/p>\n\n\n\n<p><a href=\"https:\/\/rnatics.com\/pipeline\/\" target=\"_blank\" rel=\"noreferrer noopener\">RCS-21<\/a> RCS-21 is an RNA-based drug that patients inhale via an inhaler. In the lungs, the drug specifically targets certain immune cells in the alveoli, called macrophages. RCS-21 inhibits the molecule microRNA-21 there. This molecule is considered a key trigger for pathological inflammation and scarring of lung tissue.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&quot;Further progress towards clinical trials is an important milestone in translating our research into a potential therapy,&quot;<\/p>\n<\/blockquote>\n\n\n\n<p>explain <strong>Stefan Engelhardt<\/strong>, CSO and co-founder of Rnatics, and <strong>Christina Beck<\/strong>, Project Manager.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">New approach to combat lung damage<\/h2>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&quot;Rnatics&#039; approach to macrophage-directed RNA therapy is extremely innovative, and I look forward to strategically supporting this program,&quot;<\/p>\n<\/blockquote>\n\n\n\n<p>thinks <strong>Thomas Thum<\/strong>, board member.<\/p>\n\n\n\n<p>Klaus Rabe, CMO and co-founder, emphasizes that by addressing the root cause of inflammatory and fibrotic lung diseases, RCS-21 has the potential to offer new hope to patients with idiopathic pulmonary fibrosis (IPF) and related conditions, for whom there are currently only limited effective treatment options. According to CEO and co-founder Thomas Frischmuth, the company expects initial clinical data in the coming months, which will provide initial insights into the therapy&#039;s potential.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Munich-based biotech startup Rnatics has secured \u20ac2.7 million in funding from the German government. The funds will be used for the clinical development of an inhalable RNA drug to treat inflammatory and fibrotic lung diseases.<\/p>","protected":false},"author":42,"featured_media":79231,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5633,1],"tags":[371,52,4321,4498],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Meilenstein in der Behandlung von Lungenerkrankungen? Rnatics erh\u00e4lt 2,7 Millionen Euro - Munich Startup<\/title>\n<meta name=\"description\" content=\"Rnatics erh\u00e4lt 2,7 Millionen Euro f\u00fcr die klinische Entwicklung des inhalativen RNA-Wirkstoffs RCS-21 gegen Lungenerkrankungen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/117683\/rnatics-receives-new-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Meilenstein in der Behandlung von Lungenerkrankungen? Rnatics erh\u00e4lt 2,7 Millionen Euro - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Rnatics erh\u00e4lt 2,7 Millionen Euro f\u00fcr die klinische Entwicklung des inhalativen RNA-Wirkstoffs RCS-21 gegen Lungenerkrankungen.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/117683\/rnatics-receives-new-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T08:46:00+00:00\" \/>\n<meta name=\"author\" content=\"Saskia Doll\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saskia Doll\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/\",\"url\":\"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/\",\"name\":\"Meilenstein in der Behandlung von Lungenerkrankungen? Rnatics erh\u00e4lt 2,7 Millionen Euro - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2022\/01\/1639177_low.jpg\",\"datePublished\":\"2026-03-04T08:46:00+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5\"},\"description\":\"Rnatics erh\u00e4lt 2,7 Millionen Euro f\u00fcr die klinische Entwicklung des inhalativen RNA-Wirkstoffs RCS-21 gegen Lungenerkrankungen.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2022\/01\/1639177_low.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2022\/01\/1639177_low.jpg\",\"width\":2400,\"height\":1600,\"caption\":\"Stefan Hanns Engelhardt, Professor f\u00fcr Pharmakologie und Toxikologie an der TU M\u00fcnchen\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meilenstein in der Behandlung von Lungenerkrankungen? Rnatics erh\u00e4lt 2,7 Millionen Euro\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5\",\"name\":\"Saskia Doll\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g\",\"caption\":\"Saskia Doll\"},\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/doll\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2022\/01\/1639177_low.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A milestone in the treatment of lung diseases? Rnatics receives \u20ac2.7 million - Munich Startup","description":"Rnatics receives 2.7 million euros for the clinical development of the inhaled RNA drug RCS-21 against lung diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/117683\/rnatics-receives-new-funding\/","og_locale":"en_US","og_type":"article","og_title":"Meilenstein in der Behandlung von Lungenerkrankungen? Rnatics erh\u00e4lt 2,7 Millionen Euro - Munich Startup","og_description":"Rnatics erh\u00e4lt 2,7 Millionen Euro f\u00fcr die klinische Entwicklung des inhalativen RNA-Wirkstoffs RCS-21 gegen Lungenerkrankungen.","og_url":"https:\/\/cms.munich-startup.net\/en\/117683\/rnatics-receives-new-funding\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2026-03-04T08:46:00+00:00","author":"Saskia Doll","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Saskia Doll","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/","url":"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/","name":"A milestone in the treatment of lung diseases? Rnatics receives \u20ac2.7 million - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2022\/01\/1639177_low.jpg","datePublished":"2026-03-04T08:46:00+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5"},"description":"Rnatics receives 2.7 million euros for the clinical development of the inhaled RNA drug RCS-21 against lung diseases.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2022\/01\/1639177_low.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2022\/01\/1639177_low.jpg","width":2400,"height":1600,"caption":"Stefan Hanns Engelhardt, Professor f\u00fcr Pharmakologie und Toxikologie an der TU M\u00fcnchen"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/117683\/rnatics-erhaelt-neue-foerderung\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Meilenstein in der Behandlung von Lungenerkrankungen? Rnatics erh\u00e4lt 2,7 Millionen Euro"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5","name":"Saskia Doll","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g","caption":"Saskia Doll"},"url":"https:\/\/cms.munich-startup.net\/en\/author\/doll\/"}]},"og_image":[{"width":2400,"height":1600,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2022\/01\/1639177_low.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1772552140:25","_edit_last":"25","_yoast_wpseo_focuskw":"Rnatics","_yoast_wpseo_metadesc":"Rnatics erh\u00e4lt 2,7 Millionen Euro f\u00fcr die klinische Entwicklung des inhalativen RNA-Wirkstoffs RCS-21 gegen Lungenerkrankungen.","_yoast_wpseo_linkdex":"70","_thumbnail_id":"79231","wbounce_status":"default","_yoast_wpseo_primary_category":"5633","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"90","ms_image_format":"contentwidth","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"1","_suppress_startupbox":"field_60a64b0b6efc6","_yoast_wpseo_estimated-reading-time-minutes":"2","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/117683"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/42"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=117683"}],"version-history":[{"count":4,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/117683\/revisions"}],"predecessor-version":[{"id":117688,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/117683\/revisions\/117688"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/79231"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=117683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=117683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=117683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}